The indications for the introduction of GLP-1 analogs to treatment include a BMI of ≥30 kg/m2 or a BMI of ≥27 kg/m2 and at least one weight-related comorbidity including hypertension, dyslipidemia, type 2 DM, or obstructive sleep apnea [18]. This evidence concerns the gene GCG and Hypertension.